Sedative and cardiopulmonary effects of dexmedetomidine infusions randomly receiving, or not, butorphanol in standing horses.

Dexmedetomidine (DEX) alone, or combined with butorphanol (BUT), may be administered by constant rate infusions (CRIs) in standing horses. This blinded, randomised, crossover study in six healthy adult horses aimed to determine the sedative and cardiopulmonary effects of DEX (dexmedetomidine (3.5 µg/kg+5 µg/kg/hour CRI) and DEX/BUT (dexmedetomidine (3.5 µg/kg+3.5 µg/kg/hour CRI) and butorphanol (20 µg/kg+24 µg/kg/hour CRI)). Head height above ground (HHAG), ataxia, responses to tactile/auditory stimuli and cardiopulmonary variables were recorded before, at 5/15/30/60/90 minutes and after CRIs terminated (15/30/60 minutes). Repeated measures analysis of variance with Tukey-Kramer test were used for cardiopulmonary values (mean±SD) and HHAG reduction (per cent), and Friedman's and Dunn's for non-parametric data (P<0.05). Maximum HHAG reductions of 54 per cent (DEX) and 58 per cent (DEX/BUT) occurred at 15 minutes, with ataxia for 15 minutes in both treatments. Responses to stimuli were reduced for 30 minutes in both treatments, and auditory up to 60 minutes in DEX. Cardiopulmonary effects typical of α2-agonists were observed, with no differences between treatments. At the doses and rates reported here, both regimens provided clinically sufficient sedation for only 30 minutes.

Long-term evaluation of a new ventriculoperitoneal shunt valve system in a dog.

OBJECTIVE: To report on the use of a new ventriculoperitoneal shunt (VPS) valve system utilized in a dog with hydrocephalus and to describe the clinical course over 20 months after implantation. CASE SUMMARY: A 3-month-old female Lhasa Apso dog was presented with lateral strabismus, domed calvarium, and visual deficits. A lateral skull radiograph revealed a persistent fontanelle. Transfontanellar ultrasonographic examination and computed tomographic examination showed excessive accumulation of fluid within the ventricles. The owner had observed symptoms as early as 1 month after birth, suggesting congenital hydrocephalus. A VPS with a new valve system that inhibits cerebrospinal fluid overdrainage and obstruction of the catheter was implanted. The dog showed clinical improvement 48 hours after the procedure. Twenty days after shunt implantation, another computed tomography scan was performed that showed reduction in ventricle size. The evaluation of VPS patency was carried out 20 months after surgery and demonstrated that the system was working properly without obstruction. NEW OR UNIQUE INFORMATION PROVIDED: There are reports in the literature describing the use of several devices to perform VPS in dogs. A new device not previously described in the veterinary literature was used in this case report, and according to the manufacturer's description, this device inhibits proteinaceous build-up, which is usually responsible for subsequent catheter obstructions.